3-Oxo-4-aza-5alpha-alphandrost-1-ene-17beta-carboxylic Acid

1H-Indeno[5,4-f]quinoline-7-carboxylic acid, 2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-4a,6a-dimethyl-2-oxo-, (4aR,4bS,6aS,7S,9aS,9bS,11aR)-; 4-Azaandrost-1-ene-17-carboxylic acid, 3-oxo-, (5alpha,17beta)-; (5alpha,17beta)-N-[(2,5-Bis(trifluoromethyl)-phenyl]-3-oxo-4-aza-5-androst-1-ene-17-carboxylic acid; 1H-Indeno[5,4-f]quinoline-7-carboxylic acid, 2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-4a,6a-dimethyl-2-oxo-, [4aR-(4aalpha,4bbeta,6aalpha,7alpha,9abeta,9balpha,11abeta)]-; 3-Oxo-4-aza-5alpha-androst-1-ene-17-carboxylic acid; 3-Oxo-4-aza-5alpha-androst-1-ene-17beta-carboxylic acid; Dutasteride Imp A (EP); Finasteride Acid; Dutasteride Acid Impurity; Dutasteride related; Dutasteride Impurity A

InChI=1S/C19H27NO3/c1-18-9-7-13-11(12(18)4-5-14(18)17(22)23)3-6-15-19(13,2)10-8-16(21)20-15/h8,10-15H,3-7,9H2,1-2H3,(H,20,21)(H,22,23)/t11-,12-,13-,14+,15+,18-,19+/m0/s1